These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19199912)

  • 1. Current constructs and targets in clinical development for antibody-based cancer therapy.
    Deckert PM
    Curr Drug Targets; 2009 Feb; 10(2):158-75. PubMed ID: 19199912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody-based therapy.
    von Mehren M; Weiner LM
    Curr Opin Oncol; 1996 Nov; 8(6):493-8. PubMed ID: 8971469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody therapy of cancer.
    Jurcic JG; Scheinberg DA; Houghton AN
    Cancer Chemother Biol Response Modif; 1994; 15():152-75. PubMed ID: 7779584
    [No Abstract]   [Full Text] [Related]  

  • 6. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using antibodies to target cancer therapeutics.
    Goldenberg DM; Sharkey RM
    Expert Opin Biol Ther; 2012 Sep; 12(9):1173-90. PubMed ID: 22650606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-based therapeutics in oncology.
    Ross J; Gray K; Schenkein D; Greene B; Gray GS; Shulok J; Worland PJ; Celniker A; Rolfe M
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):107-21. PubMed ID: 12597355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future prospects of monoclonal antibodies as magic bullets in immunotherapy.
    Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ
    Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies in the therapy of colon cancer.
    Welt S; Ritter G
    Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant antibodies in cancer therapy.
    Nayeem MS; Khan RH
    Curr Protein Pept Sci; 2006 Apr; 7(2):165-70. PubMed ID: 16611141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments.
    Dillman RO
    Cancer Invest; 2001; 19(8):833-41. PubMed ID: 11768037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies in cancer detection and therapy.
    Goldenberg DM
    Am J Med; 1993 Mar; 94(3):297-312. PubMed ID: 8452154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies and their fragments as anti-cancer agents.
    Schaedel O; Reiter Y
    Curr Pharm Des; 2006; 12(3):363-78. PubMed ID: 16454750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering antibodies for clinical applications in cancer.
    Chester K; Pedley B; Tolner B; Violet J; Mayer A; Sharma S; Boxer G; Green A; Nagl S; Begent R
    Tumour Biol; 2004; 25(1-2):91-8. PubMed ID: 15192316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.
    Lorberboum-Galski H
    Expert Opin Drug Deliv; 2011 May; 8(5):605-21. PubMed ID: 21453191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.